By: Andrea Stippler, Niels Eckstein, Elmar Kroth
Stippler A, Eckstein N, Kroth E. To switch or not to switch – German physicians´ views on proposed new OTC medicines. SelfCare 2019;10(1)11-23.
Rx-to-OTC switch
To switch or not to switch – German physicians´ views on proposed new OTC medicines
EDITORIAL
by Soller R W
Safe Use Conditions proposed by FDA may re-open door for switch in US: Has the OTC Drug Facts Label fallen victim to the Peter Principle? SelfCare 2012;3(2):19-20
A PROTOTYPE COMPUTER KIOSK AND ALGORITHM TO ASSIST CONSUMERS WITH SELF-SELECTION
by Schifkovitz D
Schifkovitz D. A prototype computer kiosk and algorithm to assist consumers with self-selection. SelfCare 2012;3(4):84-86
GUIDING PRINCIPLES FOR ADDRESSING RX-TO-OTC SWITCH IN THE CONTEXT OF NOVEL CONDITIONS OF USE FOR NONPRESCRIPTION MEDICINES
by Soller RW, Tong T, Koda Kimble MA, Juhl R, Lam YWF, Rice L
Soller RW, Tong T, Koda Kimble MA, Juhl R, Lam YWF, Rice L. Guiding principles for addressing Rx-to-OTC switch in the context of novel conditions of use for nonprescription medicines. SelfCare 2012;3(4):78-83
FDA MARCH 22-23, 2012 HEARING ON RX TO OTC SWITCH
by Woodcock J
Woodcock J. Presentation to FDA hearing on Rx to OTC switch. SelfCare 2012;3(4):75-77
USING INNOVATIVE TECHNOLOGIES AND OTHER CONDITIONS OF SAFE USE TO EXPAND WHICH DRUG PRODUCTS CAN BE CONSIDERED NONPRESCRIPTION; PUBLIC HEARING
Notice of public hearing. SelfCare 2012;3(4):69-74
EDITORIAL
by Soller R W, Mann S
Thought leaders of self-care announcing a new program of leading public commentaries on self-care. SelfCare 2012;3(4):67-68
THE SWITCH CONSIDERATIONS LIST: ‘CONSIDERATIONS FOR RX-TO-OTC SWITCH’ REFINED BY A CRITICAL SYNTHESIS OF FDA COMMENTS ON EXPANDED ACCESS FOR NALOXONE
by Soller RW, Shaheen C
Soller RW, Shaheen C. The Switch Considerations List: ‘Considerations for Rx-to-OTC Switch’ Refined by a Critical Synthesis of FDA Comments on Expanded Access for Naloxone. SelfCare 2012;3(6):121-137
The Food and Drug Administration (FDA) recently held a meeting to explore new paradigms for drug availability under the regulatory rubric of novel conditions of nonprescription drug use. Subsequent to this meeting, FDA held a workshop on naloxone for prevention of death from opioid overdose. This represented the first publicly discussed switch candidate for novel conditions of nonprescription drug use.
REGULATORY SCIENCE IMPLICATIONS OF EXPANDED MEDICATION ACCESS FOR TREATMENT OF OVERACTIVE BLADDER
by R William Soller
Soller RW. Regulatory Science Implications of Expanded Medication Access for Treatment of Overactive Bladder. SelfCare 2013;4(2):23-37
PLAN B IN THE CRUCIBLE OF SCIENCE AND POLITICS
by R William Soller
Soller RW. Plan B in the Crucible of Science and Politics. SelfCare 2013;4(3):61-65